Humana (NYSE:HUM) Raised to Outperform at Raymond James

Humana (NYSE:HUM - Get Free Report) was upgraded by research analysts at Raymond James from a "market perform" rating to an "outperform" rating in a note issued to investors on Thursday, MarketBeat reports. The brokerage currently has a $315.00 target price on the insurance provider's stock. Raymond James' target price would indicate a potential upside of 21.99% from the company's current price.

A number of other equities analysts have also recently issued reports on the stock. Morgan Stanley cut their target price on shares of Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 12th. Guggenheim assumed coverage on Humana in a research note on Wednesday, April 9th. They set a "buy" rating and a $326.00 price objective for the company. Mizuho boosted their price target on shares of Humana from $305.00 to $316.00 and gave the company an "outperform" rating in a report on Wednesday, April 9th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $283.00 price objective on shares of Humana in a report on Wednesday, February 12th. Finally, Cantor Fitzgerald reissued a "neutral" rating and set a $290.00 target price on shares of Humana in a research note on Wednesday, February 12th. Eighteen investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $287.76.

Humana Stock Up 0.8 %

NYSE:HUM traded up $2.17 during mid-day trading on Thursday, reaching $258.21. The stock had a trading volume of 1,740,020 shares, compared to its average volume of 1,753,030. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The company has a market capitalization of $31.16 billion, a price-to-earnings ratio of 25.95, a price-to-earnings-growth ratio of 2.05 and a beta of 0.49. Humana has a 1-year low of $213.31 and a 1-year high of $406.46. The stock's 50 day simple moving average is $266.17 and its two-hundred day simple moving average is $270.73.

Humana (NYSE:HUM - Get Free Report) last issued its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, topping the consensus estimate of $10.07 by $1.51. The company had revenue of $32.11 billion during the quarter, compared to analyst estimates of $32 billion. Humana had a return on equity of 11.70% and a net margin of 1.02%. The business's revenue was up 8.4% on a year-over-year basis. During the same quarter last year, the firm earned $7.23 EPS. Equities analysts anticipate that Humana will post 16.47 EPS for the current year.

Institutional Investors Weigh In On Humana

A number of institutional investors and hedge funds have recently bought and sold shares of HUM. Dodge & Cox boosted its holdings in Humana by 106.7% during the fourth quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider's stock worth $2,587,345,000 after buying an additional 5,264,045 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Humana by 15.8% during the 4th quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider's stock valued at $3,254,899,000 after acquiring an additional 1,751,857 shares during the last quarter. Norges Bank bought a new stake in shares of Humana during the 4th quarter worth $416,202,000. Pzena Investment Management LLC grew its holdings in shares of Humana by 44.0% in the 4th quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider's stock worth $915,736,000 after acquiring an additional 1,103,132 shares during the last quarter. Finally, Boston Partners raised its position in shares of Humana by 435.8% during the fourth quarter. Boston Partners now owns 1,098,702 shares of the insurance provider's stock worth $279,236,000 after purchasing an additional 893,637 shares during the period. 92.38% of the stock is owned by institutional investors and hedge funds.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.